PROLOG study: main results and guidance for further action
Abstract
The article contains main results of PROLOG study, that compared effectiveness of controlled arterial hypertension therapy in step-wise antihypertensive treatment scheme: ACE inhibitor, spirapril, with addiction, if necessary, of diuretic hydrochlorthiazide, and beta-adrenoblocker atenolol (intervention group), vs standard treatment, prescribed by out-patient clinic doctors (control group). The follow-up period lasted for one year. Throughout the study period, systolic and diastolic blood pressure levels were significantly lower in intervention group than in control one. Cardiovascular event risk reduction was more pronounced in intervention group: 33% vs 22% in control group. PROLOG study results coincide with data from other large-scale, randomized, controlled studies.
About the Authors
S. Yu. Martsevich
Society of Cardiology of the Russian Federation
Russian Federation
Russian Federation
S. A. Shalnova
Society of Cardiology of the Russian Federation
Russian Federation
Russian Federation
A. D. Deev
Society of Cardiology of the Russian Federation
Russian Federation
Russian Federation
N. P. Kutishenko
Society of Cardiology of the Russian Federation
Russian Federation
Russian Federation
V. V. Yakusevich
Society of Cardiology of the Russian Federation
Russian Federation
Russian Federation
References
1. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профил забол укреп здор 2001; 2: 3-7.
2. Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin Therap 2004; 26: 631-48.
3. Андреева Г.Ф., Горбунов В.М., Марцевич С.Ю. Оценка уровня информированности о своем заболевании больных со стабильной артериальной гипертензией. РФК 2005; 1: 9-12.
4. Оганисян Н.С., Дмитриева Н.А., Кочетков А.М., Марцевич С.Ю. Особенности диагностики и вторичной профилактики артериальной гипертонии по результатам опроса врачей. РФК 2006; 2: 37-42.
5. Шальнова С.А., Марцевич С.Ю., Деев А.Д., и др. Исследование «ПРОЛОГ» как способ доказательства возможностей современной терапии. РФК 2005; 1: 4-8.
6. Шальнова С.А., Марцевич С.Ю., Деев А.Д. и др. Исследование ПРОЛОГ: снижение риска сердечно-сосудистых заболеваний у больных артериальной гипертонией под влиянием антигипертензивной терапии. Кардиоваск тер профил 2005; 4: 10-5.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.
8. Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.
9. Лукина Ю.В. Лекарственные препараты и курение. РФК 2005; 1: 31-6.
10. Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
Review
For citations:
Martsevich S.Yu., Shalnova S.A., Deev A.D., Kutishenko N.P., Yakusevich V.V. PROLOG study: main results and guidance for further action. Cardiovascular Therapy and Prevention. 2006;5(6):23-26. (In Russ.)
Views:
540
Email this article 
